{"component": "definition", "props": {"groups": [{"snippet": "means: Impax Laboratories, Inc.; its directors, officers, employees, agents, representatives, successors, and assigns; and its joint ventures, subsidiaries, divisions, groups, and affiliates, in each case controlled by Impax Laboratories, Inc. (including, without limitation, Impax Laboratories, LLC), and the respective directors, officers, employees, agents, representatives, successors, and assigns of each.", "samples": [{"hash": "4lePBAyPeJD", "uri": "https://www.ftc.gov/system/files/documents/cases/1810017_amneal_impax_decision_and_order_4-27-18.pdf", "label": "www.ftc.gov", "score": 8.1704312115, "published": false}, {"hash": "gQlm0T5LjpX", "uri": "https://www.ftc.gov/system/files/documents/cases/181_0017_c4650_amneal_impax_decision_and_order.pdf", "label": "www.ftc.gov", "score": 7.2546201232, "published": false}, {"hash": "h5FFCivgXOm", "uri": "https://www.ftc.gov/system/files/documents/cases/1810017_amneal_impax_order_to_maintain_assets.pdf", "label": "www.ftc.gov", "score": 7.2026009582, "published": false}], "size": 12, "snippet_links": [{"key": "joint-ventures", "type": "definition", "offset": [127, 141]}, {"key": "each-case", "type": "definition", "offset": [195, 204]}, {"key": "without-limitation", "type": "clause", "offset": [256, 274]}], "hash": "c25600a81ddd66c9a9d1e522c4ef970e", "id": 1}, {"snippet": "means Impax Laboratories, Inc.", "samples": [{"hash": "5Avf7BO4iR", "uri": "/contracts/5Avf7BO4iR#impax", "label": "License Agreement", "score": 31.340862423, "published": true}, {"hash": "rXQPqffQoE", "uri": "/contracts/rXQPqffQoE#impax", "label": "License Agreement (Salix Pharmaceuticals LTD)", "score": 26.1170431211, "published": true}, {"hash": "6Ae0m4yH6Pj", "uri": "/contracts/6Ae0m4yH6Pj#impax", "label": "License Agreement (Santarus Inc)", "score": 23.173853525, "published": true}], "size": 9, "snippet_links": [], "hash": "70b8ab8cacf3795bcd67c630e0349e91", "id": 2}, {"snippet": "has the meaning set forth in the preamble to this Agreement.", "samples": [{"hash": "kBjRuCNovGh", "uri": "/contracts/kBjRuCNovGh#impax", "label": "Stock and Warrant Purchase Agreement (Evergreen Solar Inc)", "score": 21.0, "published": true}, {"hash": "dbvQ2UdvWpd", "uri": "/contracts/dbvQ2UdvWpd#impax", "label": "Stock and Warrant Purchase Agreement (Evergreen Solar Inc)", "score": 18.0, "published": true}, {"hash": "bTGn7u1Rfli", "uri": "/contracts/bTGn7u1Rfli#impax", "label": "Stock and Warrant Purchase Agreement (Chleboski Richard G)", "score": 18.0, "published": true}], "size": 7, "snippet_links": [{"key": "the-preamble", "type": "clause", "offset": [29, 41]}, {"key": "to-this-agreement", "type": "clause", "offset": [42, 59]}], "hash": "1f3de82c531442eb5b3bb26b80892c0d", "id": 3}, {"snippet": "means (1) prior to the Impax Conversion, Impax Laboratories, Inc., a Delaware corporation, and (2) after the consummation of the Impax Conversion, Impax Laboratories, LLC, a Delaware limited liability company.", "samples": [{"hash": "E65F94V0gi", "uri": "/contracts/E65F94V0gi#impax", "label": "Term Loan Credit Agreement (Amneal Pharmaceuticals, Inc.)", "score": 34.8672142368, "published": true}, {"hash": "k6HLifH8eJE", "uri": "/contracts/k6HLifH8eJE#impax", "label": "Revolving Credit Agreement (Amneal Pharmaceuticals, Inc.)", "score": 29.3449691992, "published": true}, {"hash": "dnPxhmQLkpp", "uri": "/contracts/dnPxhmQLkpp#impax", "label": "Term Loan Credit Agreement (Amneal Pharmaceuticals, Inc.)", "score": 29.3449691992, "published": true}], "size": 6, "snippet_links": [{"key": "prior-to-the", "type": "clause", "offset": [10, 22]}, {"key": "impax-conversion", "type": "definition", "offset": [23, 39]}, {"key": "delaware-corporation", "type": "clause", "offset": [69, 89]}, {"key": "consummation-of-the", "type": "clause", "offset": [109, 128]}, {"key": "a-delaware-limited-liability-company", "type": "clause", "offset": [172, 208]}], "hash": "7f658b718a714093705bdde84ddc39ed", "id": 4}, {"snippet": "means Impax Laboratories LLC, a Delaware limited liability company.", "samples": [{"hash": "fQbkzAwQjTO", "uri": "/contracts/fQbkzAwQjTO#impax", "label": "Limited Liability Company Agreement (Amneal Pharmaceuticals, Inc.)", "score": 29.3449691992, "published": true}, {"hash": "4G8gcw2VcuP", "uri": "/contracts/4G8gcw2VcuP#impax", "label": "Limited Liability Company Agreement (Amneal Pharmaceuticals, Inc.)", "score": 29.3449691992, "published": true}, {"hash": "ES9tbHrv9p", "uri": "/contracts/ES9tbHrv9p#impax", "label": "Business Combination Agreement (Impax Laboratories Inc)", "score": 28.8877481177, "published": true}], "size": 5, "snippet_links": [{"key": "a-delaware-limited-liability-company", "type": "clause", "offset": [30, 66]}], "hash": "62f7b8ea795797baa45f3420ae29a41c", "id": 5}, {"snippet": "means Impax Laboratories, Inc., a corporation organized, existing, and doing business under and by virtue of the laws of the State of Delaware, with its headquarters address at 30831 Huntwood Avenue, Hayward, CA 94544.", "samples": [{"hash": "gorp0sn6G9t", "uri": "https://www.ftc.gov/sites/default/files/documents/cases/2010/01/0910116watsonord.pdf", "label": "www.ftc.gov", "score": 9.4476386037, "published": false}, {"hash": "i4VdagR0fYm", "uri": "https://www.ftc.gov/sites/default/files/documents/cases/2009/12/0910116watsondo.pdf", "label": "www.ftc.gov", "score": 9.3709787817, "published": false}, {"hash": "crVD3c3i6e6", "uri": "https://www.ftc.gov/sites/default/files/documents/cases/2010/01/100115watsondo.pdf", "label": "www.ftc.gov", "score": 5.0191649555, "published": false}], "size": 5, "snippet_links": [{"key": "a-corporation", "type": "clause", "offset": [32, 45]}, {"key": "doing-business", "type": "definition", "offset": [71, 85]}, {"key": "the-laws", "type": "definition", "offset": [109, 117]}, {"key": "state-of-delaware", "type": "clause", "offset": [125, 142]}], "hash": "3c411d584299ad5de8d1e0e97ac2f444", "id": 6}, {"snippet": "has the meaning set forth in the preamble hereto.", "samples": [{"hash": "1erUPiDzGkF", "uri": "/contracts/1erUPiDzGkF#impax", "label": "Distribution, License, Development and Supply Agreement (Impax Laboratories Inc)", "score": 23.250513347, "published": true}, {"hash": "gWjvbvqNQO7", "uri": "/contracts/gWjvbvqNQO7#impax", "label": "Distribution, License, Development and Supply Agreement (Impax Laboratories Inc)", "score": 23.0971937029, "published": true}], "size": 2, "snippet_links": [{"key": "the-preamble", "type": "clause", "offset": [29, 41]}], "hash": "8bccce1d0361cba936f9f507ba47a5ce", "id": 7}, {"snippet": "means Impax Laboratories, Inc., a corporation organized, existing and doing business under and by virtue of the laws of the State of Delaware with its principal executive offices located at 30831 Huntwood Avenue, Hayward, California 94544.", "samples": [{"hash": "jIe2dJcIb52", "uri": "https://www.ftc.gov/es/system/files/documents/cases/160915teva-allergan-do.pdf", "label": "www.ftc.gov", "score": 8.3524982888, "published": false}, {"hash": "huE2BVqzvdj", "uri": "https://www.ftc.gov/es/system/files/documents/cases/160727tevaallergando.pdf", "label": "www.ftc.gov", "score": 8.2826830938, "published": false}], "size": 2, "snippet_links": [{"key": "a-corporation", "type": "clause", "offset": [32, 45]}, {"key": "doing-business", "type": "definition", "offset": [70, 84]}, {"key": "the-laws", "type": "definition", "offset": [108, 116]}, {"key": "state-of-delaware", "type": "clause", "offset": [124, 141]}, {"key": "principal-executive-offices", "type": "definition", "offset": [151, 178]}], "hash": "91e456343970a0e25d32cae9b371f13e", "id": 8}, {"snippet": "means [Impax Laboratories LLC]2, a Delaware limited liability company.", "samples": [{"hash": "YjRNfSDeMF", "uri": "/contracts/YjRNfSDeMF#impax", "label": "Business Combination Agreement (Impax Laboratories Inc)", "score": 28.7919233402, "published": true}], "size": 2, "snippet_links": [{"key": "a-delaware-limited-liability-company", "type": "clause", "offset": [33, 69]}], "hash": "b598e76574a6125040fb1c0e8fbf100c", "id": 9}, {"snippet": "means: Impax Laboratories, Inc.; its directors, officers, employees, agents, representatives, successors, and assigns; and its joint ventures, subsidiaries, divisions, groups, and affiliates, in each case controlled by Impax Laboratories, Inc. (including, without limitation, Impax Laboratories, LLC), and the", "samples": [{"hash": "aYy0tLiW7cw", "uri": "https://www.ftc.gov/system/files/documents/commission_decision_volumes/volume-165/ftc_volume_decision_165_jan_-_jun_2018pages_1208-1551.pdf", "label": "www.ftc.gov", "score": 10.1074606434, "published": false}], "size": 1, "snippet_links": [{"key": "joint-ventures", "type": "definition", "offset": [127, 141]}, {"key": "each-case", "type": "definition", "offset": [195, 204]}, {"key": "without-limitation", "type": "clause", "offset": [256, 274]}], "hash": "b7e1900b6acb29c5550d34ed55c7efc6", "id": 10}], "next_curs": "ClISTGoVc35sYXdpbnNpZGVyY29udHJhY3Rzci4LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIOaW1wYXgjMDAwMDAwMGEMogECZW4YACAA", "definition": {"title": "Impax", "snippet": "means: Impax Laboratories, Inc.; its directors, officers, employees, agents, representatives, successors, and assigns; and its joint ventures, subsidiaries, divisions, groups, and affiliates, in each case controlled by Impax Laboratories, Inc. (including, without limitation, Impax Laboratories, LLC), and the respective directors, officers, employees, agents, representatives, successors, and assigns of each.", "size": 55, "id": "impax", "examples": ["All notices or communications hereunder shall be in writing, addressed as follows (or to such other address as either party may have furnished to the other in writing by like notice): To the Company: <strong>Impax</strong> Laboratories, Inc.", "This Agreement shall be binding on each of <strong>Impax</strong> and Medicis and their respective permitted successors and assigns.", "<strong>Impax</strong> and Medicis are acting under this Agreement as independent contractors and neither shall be considered an agent of, or joint venturer with, the other.", "<strong>Impax</strong> agrees that it shall not challenge any of the foregoing acknowledgements and agreements concerning injunctive relief in any proceeding brought by Medicis.", "If Medicis is interested in co-developing such product with <strong>Impax</strong>, then Medicis shall provide <strong>Impax</strong>, within thirty (30) days after <strong>Impax</strong>\u2019s notice, with a written proposal of the terms under which the parties would co-develop such product.", "<strong>Impax</strong> acknowledges and agrees that it shall have no right under this Agreement to make, have made, use, sell, distribute, market, exploit or otherwise commercialize the New Product except in the course of performing its obligations under the Development Program.", "Within thirty (30) days following the end of each calendar quarter during the term of the Development Program, <strong>Impax</strong> shall prepare and deliver to Medicis a written summary report which shall describe the research performed to date under the Development Program and all results, analysis and conclusions thereof.", "For the purposes of this Section 11.6, the \u201cRelevant Business Unit\u201d shall mean, with respect to <strong>Impax</strong>, the generics division of <strong>Impax</strong>, and with respect to Medicis, the medical dermatology division of Medicis.", "The term of the Steering Committee shall commence on the Effective Date and continue until <strong>Impax</strong> has completed its obligations under the Development Plan.", "Subject to Section 7.2 below, this Agreement shall expire on the latest of (a) expiration of Medicis\u2019 obligation to pay royalties to <strong>Impax</strong> under Section 6.4, (b) expiration of Medicis\u2019 obligation to pay make Authorized Product-based payments to <strong>Impax</strong> under Section 6.5, and (c) expiration of <strong>Impax</strong>\u2019s obligation to pay royalties to Medicis under Section 6.3. The license grants under Section 3.2 shall survive any such expiration in accordance with the terms of Section 3.2."], "related": [["bms", "BMS", "BMS"], ["novartis", "Novartis", "Novartis"], ["merck", "Merck", "Merck"], ["abbott", "Abbott", "Abbott"], ["pfizer", "Pfizer", "Pfizer"]], "related_snippets": [], "updated": "2025-07-07T00:16:40+00:00"}, "json": true, "cursor": ""}}